All patients were investigated by a trained clinical geneticist (F.M., Y.A., M.R., O.A., P.O.S.K., K.D.)
(jofem.org) The best-case signal: modest weight loss in a shorter trial A frequently cited 12-week randomized trial result (as summarized in reviews) reported: ~2.6 kg average loss with AOD-9604 1 mg/day vs ~0.8 kg with placebo (PMC) This is the kind of result that can be statistically meaningful, clinically modest, and very sensitive to study design (diet, activity, baseline metabolic status, adherence)
reported that BPC157 promotes angiogenesis via VEGFR2 upregulation [16], how BPC157 interacts with VEGFR2, whether it physically binds, and the mechanism underlying VEGFR2 upregulation remain unclear
Supports the body's natural healing processes